DNLI Financials

Income Statement
MetricQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
137.4M
-0.0%
137.4M
-0.1%
137.4M
+1.8%
135.0M
-7.3%
145.6M
R&D
103.8M
+6.1%
97.9M
-4.0%
102.0M
-0.7%
102.7M
-11.6%
116.2M
SG&A
33.5M
-15.1%
39.5M
+11.2%
35.5M
+10.0%
32.3M
+9.9%
29.4M
Operating Income
-137357000
+0.0%
-137365000
+0.1%
-137434000
-1.8%
-134963000
+7.3%
-145580000
EBITDA
-134512000
-0.0%
-134499000
-0.0%
-134487000
-4.3%
-128917000
+10.0%
-143255000
Net Income
-128447000
+0.1%
-128549000
-1.3%
-126902000
-2.2%
-124119000
+6.7%
-132970000
EPS (Basic)
$-0.69
+5.5%
$-0.73
+1.4%
$-0.74
-2.8%
$-0.72
+7.7%
$-0.78
EPS (Diluted)
$-0.69
+5.5%
$-0.73
+1.4%
$-0.74
-2.8%
$-0.72
+7.7%
$-0.78
Shares (Diluted)
186.6M
+6.3%
175.5M
+1.8%
172.4M
+0.6%
171.4M
+0.1%
171.2M
Denali Therapeutics (DNLI) โ€” Financials